On July 3, Gelunhui, CureVac (CVAC.US), a German vaccine company, rose nearly 20% before pre-market trading, reporting $4. On the news front, GlaxoSmithKline and CureVac have redrafted their mRNA vaccine collaboration agreement in a new licensing agreement, giving GlaxoSmithKline the full rights to develop flu and COVID-19 candidate vaccines (including combination vaccines). CureVac will receive a prepayment of 400 million euros, as well as up to 1.05 billion euros in milestones and royalties. In addition, CureVac has begun a global strategy reorganization plan, which includes a 30% reduction in staff.
美股异动｜Curevac盘前涨近20% 与葛兰素史克扩大mRNA疫苗合作协议+计划裁员30%
US stock market abnormal Curevac rose nearly 20% before the market, expanded the mRNA vaccine cooperation agreement with GlaxoSmithKline, and planed to cut 30% of staff.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.